Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBP-201 in Chronic Rhinosinusitis with Nasal Polyps
2021-000585-15Phase 2Terminated
- Sponsor
- Connect Biopharma
- Start
- Aug 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic rhinosinusitis with nasal polyps (CRSwNP) comparing CBP-201 + mometasone furoate nasal spray with Placebo + mometasone furoate nasal spray (2 arms). Primary endpoints: Change in endoscopic nasal polyp score and Change in nasal congestion/obstruction score severity. Started Aug 2021; status: terminated.
02
Drugs
rademikibart
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on 2021-000585-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000585-15.